



## AstraZeneca Pharma India Limited

Regd. Office: "Avishkar", Off Bellary Road, Hebbal, Bangalore 560 024

### FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 30 SEPTEMBER 2007

Rs in lakhs (except for number of shares)

Sl No.	Particulars	Quarter ended 30.09.2007 (Unaudited)	Quarter ended 30.09.2006 (Unaudited)	Nine months ended 30.09.2007 (Unaudited)	Nine months ended 30.09.2006 (Unaudited)	Previous Accounting year ended 31.12.2006 (Audited)
1	Gross sales	7,937.66	7,450.69	23,429.37	20,984.14	28,792.16
2	Excise duty on sales	(623.70)	(591.79)	(1,886.33)	(1,679.00)	(2,351.12)
3	Net sales (1-2)	7,313.96	6,858.90	21,543.04	19,305.14	26,441.04
4	Service income	125.46	110.59	522.43	373.33	558.18
5	Other income	224.45	165.37	667.31	527.06	737.29
6	Total income (3+4+5)	7,663.87	7,134.86	22,732.78	20,205.53	27,736.51
7	<b>Expenditure</b>					
	(a) Decrease / (increase) in stock-in-trade and work-in-progress	(521.16)	(435.87)	75.80	(579.23)	(911.53)
	(b) Consumption of raw materials and packing materials	953.17	1,032.99	2,773.53	2,718.56	3,732.82
	(c) Purchase of traded goods	1,802.85	1,885.72	4,033.83	4,668.26	6,342.60
	(d) Employee cost	1,204.32	1,026.96	3,823.83	3,263.83	4,426.46
	(e) Depreciation	146.69	147.44	427.65	426.33	573.09
	(f) Other expenditure	1,538.02	1,540.25	5,233.41	4,451.54	6,074.29
	(g) Total	5,123.89	5,197.49	16,368.05	14,949.29	20,237.73
8	Interest	0.89	0.92	2.35	2.82	3.67
9	Profit from ordinary activities before tax (6-7-8)	2,539.09	1,936.45	6,362.38	5,253.42	7,495.11
10	Provision for tax, net	975.00	697.21	2,331.04	1,614.16	2,460.09
11	Provision for fringe benefit tax	35.00	21.00	112.50	116.10	137.10
12	Deferred tax charge/ (credit)	(93.46)	(18.21)	(149.14)	173.57	24.30
13	Net profit from ordinary activities after tax (9-10-11-12)	1,622.55	1,236.45	4,067.98	3,349.59	4,873.62
14	Extraordinary items	-	-	-	-	-
15	Net profit for the period (13-14)	1,622.55	1,236.45	4,067.98	3,349.59	4,873.62
16	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
17	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year					13,672.41
18	Basic and diluted earnings (Rs) per share (not annualised)	6.49	4.95	16.27	13.40	19.49
19	Public shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%

#### Notes :

- The above statement of financial results was reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 26 October 2007.
- The Company's sole business segment is Healthcare. The capital employed in this segment as on 30 September 2007 is Rs 18,240.39 lakhs (31 December 2006: Rs 14,172.41 lakhs).
- Status of investor complaints : a) Pending as on 1 July 2007 - 1 b) Received during the quarter - 6 c) Disposed off during the quarter - 6 d) Pending as on 30 September 2007 - 1. There was only 1 investor complaint carried forward from the previous quarter, which pertains to dispute on ownership of shares.
- The Board of Directors of the Company at their meeting held on 8 September 2006, approved a Scheme of Arrangement between the Company and its Shareholders for issue of secured fully paid-up redeemable non-convertible bonus debentures from the Company's General Reserve. The Shareholders and creditors of the Company have approved the said scheme. The High Court of Karnataka passed an order sanctioning the scheme pursuant to Section 391 of the Companies Act, 1956 on 6 July 2007. A certified copy of the said order was received by the Company on 11 September 2007. The Company has since applied to the Reserve Bank of India for its approval to the scheme.
- Previous period figures have been regrouped/ reclassified, wherever necessary to conform to the current period's presentation.

By Order of the Board of Directors  
For ASTRAZENECA PHARMA INDIA LIMITED

Place : Bangalore  
Date : 26 October, 2007

Anandh Balasundaram  
Managing Director

16cm(w) x 26cm(h)